Cell & Gene Therapy


12 - 14 November 2019 | Barcelona


Development, strategy and commercialisation for the cell and gene industry


What is Cell & Gene Therapy Orphan Drugs?


Over the past 10 years there has been an evolution in treatment options for rare disease patients. Cell & Gene therapies have given hope and now provide a therapeutic solution to treat & cure disease. Birthed from the World Orphan Drug Congress, which boasts 10 years of experience in the rare disease and is the largest and most established multistakeholder European orphan drug event; we have launched the Cell & Gene Therapy Co-Conference ! Join us for a spectacular 3 days in Barcelona, Spain from 12th–14th of November 2019.

The annual Cell & Gene therapy event for rare diseases will address the clinical, strategic and commercial aspects that are impacting the reality of gene therapy. Co-located with the World Orphan Drug Congress, the conference brings government authorities, payers, industry and patient advocacy groups all under one roof; with dedicated content and tracks on Cell & Gene Therapy Clinical Developments, Manufacturing (Scale Up & Delivery), Precision Medicine, Market Access, Pricing & Reimbursement.


Enjoy discussions on: 

Cell & Gene Therapies

Genome Editing

Clinical Trial Updates

Manufacture (Scale Up & Delivery)

Precision Medicine

Overcoming Regulatory Hurdles

Incorporating Patients into the Clinical Development Process

Market Access

Pricing & Reimbursement

Commercial Strategy

Pitch & Partner



Scientific Advisory Board


Wills Hughes-Wilson, Former Senior Vice President, Chief Patient Access Officer, Sobi

Wills Hughes-Wilson  
Head of Patient Access & Commercial Planning 
Mereo Biopharma

Professor Michael Linden, Former VP Gene Therapy & Head, GMI, Pfizer

Professor Michael Linden   
Former VP Gene Therapy & Head, GMI

Yann Le Cam, Chief Executive Officer, EURORDIS

Yann Le Cam  
Chief Executive Officer  

Dr Ségolène Aymé, Founder of Orphanet, Emeritus Research Director, INSERM

Dr Ségolène Aymé  
Founder of Orphanet, Emeritus Research Director

Dr Bruno Sepodes, Chair of COMP, EMA

Dr Bruno Sepodes   
Chair of COMP

Sheela Upadhyaya, Assoc. Director Highly Specialised Technologies, National Institute For Health and Care Excellence

Sheela Upadhyaya
Assoc. Director Highly Specialised Technologies
National Institute For Health and Care Excellence

Alastair Kent, Director, Genetic Alliance UK

Alastair Kent
Former Director
Genetic Alliance UK

Dr Carlo Incerti, SVP, Head of Global Medical Affairs, CMO, Genzyme, A Sanofi Company

Dr Carlo Incerti
SVP, Head of Global Medical Affairs, CMO
Genzyme, A Sanofi Company

Dr Mathew Pletcher, Head of Rare Disease Discovery, Roche

Dr Mathew Pletcher
Head of Rare Disease Discovery

Dr M Ken Kengatharan, Managing Director, Atheneos Capital

M Ken Kengatharan
Managing Partner, Atheneos Ventures and CEO
Auxesia Orion

Birgitte Volck, President Research & Development, AVROBIO

Dr Birgitte Volck
President Research & Development AVROBIO

Dr Pedro Franco, Former Scientific Administrator, EMA

Dr Pedro Franco
Former Scientific Administrator 

Rick Thompson, CEO, Findacure

Rick Thompson

Dr Alexander Natz, Secretary General, EUCOPE

Dr Alexander Natz
Secretary General

Anna Bucsics, Project Advisor, MoCA

Anna Bucsics
Project Advisor

Josie Godfrey, Former Associate Director, NICE

Josie Godfrey
Former Associate Director

Dr Diego Ardigo, Chair, IRDiRC Therapies Scientific Committee & R&D Rare Diseases Unit Head at Chiesi Group

Dr Diego Ardigo
Chair,  IRDiRC Therapies Scientific Committee & R&D Rare Diseases Unit Head at  Chiesi Group

Steve Groft, Senior Advisor to Director, National Center for Advancing Translational Sciences (NCATS), NIH

Steve Groft
Senior Advisor to Director
National Center for Advancing Translational Sciences (NCATS), NIH

Durhane Wong-Rieger, Chair of RDI and CEO, CORD

Durhane Wong-Rieger
Chair of  RDI  and CEO,  CORD

Dr Josep Torrent-Farnell, Head of the medicine division, CatSalut

Dr Josep Torrent-Farnell
Head of the medicine division

2019 Agenda Overview


2019 Agenda Overview

Who Attends?


Who attends?


Professionals in Cell and Gene Therapy:

  • CEO, CSO, CMOs in Pharma and Biotech
  • Heads in:
    • R&D, Gene Therapy and Rare diseases
    • Gene Editing
    • Precision/Personalised Medicine
    • Genetic Disorders
    • Patient Advocacy and Engagement
Academic Institutions
Associations in ATMPs 
Regulatory Affairs Professionals
Governmental Bodies
Clinicians in Genetics
Bioprocess and Manufacturing Professionals in Vectors and Scale-up
Clinical Development, Gene Therapy and Rare Diseases